- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
BioMed Research International
Volume 2014 (2014), Article ID 408068, 7 pages
Inhibitory Effect of Plant Manilkara subsericea against Biological Activities of Lachesis muta Snake Venom
1Laboratório de Venenos e Toxinas de Animais e Avaliação de Inibidores, Departamento de Biologia Celular e Molecular, Instituto de Biologia, Universidade Federal Fluminense, Outeiro de São João Batista, 3º andar, Sala 310, 24020-141 Niterói, RJ, Brazil
2Programa de Pós-Graduação em Ciências Aplicadas a Produtos para a Saúde, Faculdade de Farmácia, Universidade Federal Fluminense, 24220-900 Niterói, RJ, Brazil
3Programa de Pós-Graduação em Biotecnologia Vegetal, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, 21941-599 Rio de Janeiro, RJ, Brazil
4Centro de Pesquisa e Desenvolvimento, Fundação Ezequiel Dias, 30510-010 Belo Horizonte, MG, Brazil
Received 28 August 2013; Revised 9 December 2013; Accepted 10 December 2013; Published 8 January 2014
Academic Editor: Leonardo A. Calderon
Copyright © 2014 Eduardo Coriolano De Oliveira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Snake venom is composed of a mixture of substances that caused in victims a variety of pathophysiological effects. Besides antivenom, literature has described plants able to inhibit injuries and lethal activities induced by snake venoms. This work describes the inhibitory potential of ethanol, hexane, ethyl acetate, or dichloromethane extracts and fractions from stem and leaves of Manilkara subsericea against in vivo (hemorrhagic and edema) and in vitro (clotting, hemolysis, and proteolysis) activities caused by Lachesis muta venom. All the tested activities were totally or at least partially reduced by M. subsericea. However, when L. muta venom was injected into mice 15 min first or after the materials, hemorrhage and edema were not inhibited. Thus, M. subsericea could be used as antivenom in snakebites of L. muta. And, this work also highlights Brazilian flora as a rich source of molecules with antivenom properties.
Snakebites are a public health problem that affects mainly poor people who live in rural areas of Africa, Asia, Latin America, and Oceania [1, 2]. According to World Health Organization, it is estimated that up to five million people are bitten by snakes every year, and of these, 100,000 deaths occur annually, with 400,000 amputations and other severe health consequences (such as infection, tetanus, and scarring). Poor access to health care and scarcity of antivenoms increase the severity of the injuries and their outcomes. Snake venoms are a complex mixture of proteins, including metalloproteinase, serine protease, phospholipase A2, disintegrins, C-type lectins, myotoxins, and others [3, 4]. Lachesis muta (Bushmaster) is the longest venomous snake in the Americas and is distributed in the equatorial forests east of the Andes, ranging from eastern Ecuador, Colombia, Peru, northern Bolivia, and eastern and northern Venezuela, to Guyana, French Guyana, Surinam, and northern Brazil. Within their range, they are often abundant and are an important cause of snakebites . L. muta snakebites are mainly characterized by systemic (generalized bleeding, coagulopathy, renal failure, and shock) and local effects (pain, hemorrhage, edema, and necrosis) [6, 7]. In South America, B. jararaca has a higher incidence of accidents (95%) than L. muta (2%), but, on the other hand, L. muta bites led to more severe symptoms (listed above) and have lethality indexes three times higher than B. jararaca . Thus, reducing these indexes is necessary and must be fast.
Although antivenoms are effective against systemic effects, they do not inhibit the local effects. And, a few countries produce antivenom of adequate quality as well. Moreover, antivenoms may produce side effects and their cost of production may be expensive. In fact, worldwide the production of antivenoms is a global challenge. Due to all these limitations, the search for alternative or complementary treatment for snakebites deserves attention.
Plants are a rich source of pharmacologically active molecules that have been used for native people to treat several diseases, including snakebites. Several molecules have been isolated and tested against some lethal activities induced by snake venoms [9–11]. Manilkara subsericea (Mart.) Dubard (Sapotaceae), popularly known in Brazil as guracica, is an endemic species with edible fruits from the Brazilian Atlantic forest and grows in sandy coastal plains . A chemical composition study of genus Manilkara has shown the presence of triterpenes [13, 14], saponins , and flavonoids . The extracts of Manilkara displayed antimicrobial [13, 17, 18], antiparasitic [19, 20], anticholinesterase , against pest insects , or antitumoral  properties.
The present work investigates the ability of different ethanolic extracts of leaves and stem of M. subsericea and solvent-partitioned fractions to neutralize some in vitro and in vivo biological activities induced by L. muta snake venom.
2. Materials and Methods
All solvents were of the best analytical grade. Dimethylsulfoxide (DMSO) and azocasein were obtained from Sigma Chemical Co. (St. Louis, Missouri).
2.2. Plant Material and Extraction
Manilkara subsericea (Mart.) Dubard (Sapotaceae) was collected in January 2009 at the Jurubatiba Sandbank National Park, located in the Brazilian state of Rio de Janeiro (220° 16′ 4.93′′ S–41° 38′ 8.50′′ W), under license number 13659-2 from Instituto Brasileiro do Meio Ambiente e dos Recursos Naturais Renováveis—BAMA/SISBIO. The material was identified by Professor Dr. Marcelo Guerra Santos, a member of Department of Botany of State University of Rio de Janeiro (UERJ) and a voucher specimen was deposited in the Herbarium of UERJ and assigned under the number 13416.
The leaves (1.930 kg) and stems (0.960 kg) of M. subsericea were dried at 40°C for two days, ground, and macerated with ethanol 96% (v/v) at room temperature until exhaustion. Then, both materials were filtered and solvent evaporated using a rotary evaporator, yielding 530 g of ethanolic extract of leaves (ETL) and 169.3 g ethanolic extract of stems (ETS). These extracts were sequentially washed with solvents of increasing polarities (hexane and ethyl acetate). After complete removal of solvent under reduced pressure, using a rotary evaporator, 21.6 g hexane-soluble (HEL) and 11.5 g ethyl acetate-soluble (EAL) fractions from leaves and 12.1 g hexane (HES) and 13.7 g ethyl acetate (EAS) fractions from stems were obtained. All materials were dissolved in DMSO (30% v/v) to perform the biological assays.
2.3. Venom and Animals
Lachesis muta lyophilized venom was kindly supplied from Fundação Ezequiel Dias (FUNED), Brazil. Venom was diluted in physiological saline (1 mg/mL) and stored at −20°C until experiments. Male Swiss mice (18–20 g) were obtained from the Center of Laboratory Animals (NAL) of the Federal Fluminense University (UFF). All experiments were approved by the UFF Institutional Committee for Ethics in Animal Experimentation (protocol number 212) that were in accordance with the guidelines of the Brazilian Committee for Animal Experimentation (COBEA).
2.4. Proteolytic Activity
Proteolytic activity of L. muta venom was determined according to the method of Garcia et al. , using azocasein as substrate (0.2%, w/v, in 20 mM Tris-HCl, 8 mM CaCl2, and pH 8.8). Aliquots of L. muta venom (5–50 μg/mL) were incubated with 0.4 mL azocasein at 37°C for 90 min in a total volume of 1.2 mL. The enzymatic reaction was stopped by adding trichloroacetic acid (5%, v/v, final concentration). The tubes were centrifuged at 15,000 ×g for 3 min. Then, the supernatant was removed and mixed with 2 N NaOH, and the tubes were read at A 420 nm (spectrophotometer Hitachi U-5100) to measure the release of azo dye and recorded from the samples. An effective concentration (EC) was defined as the amount of venom (μg/mL) able to produce a variation of 0.2 units at A 420 nm. For the inhibitory experiments, one EC of L. muta venom (8.75 μg/mL) was incubated at room temperature with the extracts or fractions of M. subsericea at 1 : 10 venom : plant (w/w). Then, proteolytic activity was determined accordingly. Positive control experiments were performed by incubating L. muta venom with saline or DMSO (1% v/v).
2.5. Clotting Activity
A pool of citrated normal human plasma (diluted with equal volume of saline) was obtained from the local blood bank (University Hospital Antônio Pedro of UFF) and was mixed with L. muta snake venom (2.5–70 μg/mL) and the clotting time was monitored using an Amelung coagulometer, model KC4A (Labcon, Germany). The concentration of venom (μg/mL) that clotted plasma in 60 seconds was considered as the minimum coagulant dose (MCD). To evaluate the inhibitory effect, the extracts or fractions of M. subsericea were incubated at room temperature for 30 minutes with one MCD of venom (25 μg/mL) at 1 : 10 venom : plant (w/w), and then the mixture was added to plasma and clotting time was recorded. Negative control experiments were performed in parallel by mixing extracts or DMSO (0.5% v/v) with plasma in the absence of venom.
2.6. Hemolytic Indirect Activity
Hemolytic activity of L. muta venom was determined by the indirect hemolytic test using human erythrocytes and hen’s egg yolk emulsion as substrate . One minimum indirect hemolytic dose (MIHD) was defined as the lowest amount of L. muta venom (μg/mL) able to produce 100% hemolysis. To verify the inhibitory action of M. subsericea, one MIDH (17.6 µg/mL) was incubated at room temperature for 30 minutes with M. subsericea extracts or fractions at 1 : 10 venom : plant (w/w) ratio. Then, the hemolytic assay was performed. One hundred percent of hemolysis was obtained after lysing erythrocytes with distilled water. Negative control experiments were performed in parallel by mixing extracts or DMSO (1% v/v) with erythrocytes in the absence of venom.
2.7. Hemorrhagic Activity
Hemorrhagic lesions produced by L. muta crude venom were quantified using a procedure described by Kondo et al. , with minor modifications. Briefly, samples of venom (100 µL) were injected intradermally (i.d.) into abdominal skin of mice. Two hours later, animals were euthanized and the skin was removed, stretched, and inspected for visual changes in the inner surface or subcutaneous layers to localize hemorrhagic spots. Hemorrhage was quantified as the minimum hemorrhagic dose (MHD), defined as the amount of venom (μg/g) able to produce a hemorrhagic halo of 10 millimeters (mm) and that was the positive control. To evaluate the inhibitory effect, the extracts or fractions were incubated with two MHD (1.56 μg/g) of venom at room temperature for 30 minutes at 1 : 10 venom : plant ratio (w/w). This mixture was injected i.d. into animals and hemorrhagic activity evaluated, as described above. In another set of experiments, L. muta venom was injected i.d. 15 min first or after injection of M. subsericea extract or fractions. Hemorrhage was expressed as the mean diameter (in millimeters) of the hemorrhagic halo induced by venom in the absence and presence of the extract. Negative control experiments were performed in parallel by injecting i.d. extracts or DMSO (1% v/v) in the absence of venom.
2.8. Edematogenic Activity
Edema-inducing activity of L. muta venom was determined according to Yamakawa et al. , with modifications. Groups of mice received subcutaneously (s.c.) 50 μL of L. muta venom (0.74 μg/g) in the right paw, while the left paw received 50 μL of saline, DMSO (1% v/v), or extracts. One hour after injection, edema was evaluated as the percentage increase in weight of the right paw compared to the left one. Antiedematogenic activity was performed by incubating the extracts or fractions of M. subsericea with L. muta venom for 30 min at room temperature at 1 : 10 venom : plant ratio (w/w), and then mixture was injected s.c. into mice. Also, venom was also injected s.c. prior to or after the extract. Positive control experiments were performed by incubating L. muta venom with saline or DMSO (1% v/v) prior to injection.
2.9. Statistical Analysis
Results are expressed as means ± SEM of indicated number of animals or experiments performed. Student’s t-test was used and values of ≤ 0.05 were considered statistically significant.
3.1. The L. muta Venom-Induced Proteolysis
The crude ethanolic extract of stem (ETS) and leaves (ETL) of M. subsericea (87.5 μg/mL) inhibited 96% and 93%, respectively, the proteolytic activity of L. muta venom (8.75 μg/mL) (Figure 1). Further, ETS and ETL were partitioned using two solvents of increasing polarities, hexane, and ethyl acetate, yielding hexane-soluble and ethyl acetate-soluble fractions, respectively. The ethyl acetate-soluble fraction of stem (EAS) inhibited 99% proteolysis induced by L. muta venom, whereas the hexane one (HES) inhibited 4%. And, ethyl acetate-soluble (EAL) and hexane-soluble (HEL) fractions of the leaves inhibited 84% and 9% proteolytic activity, respectively (Figure 1).
3.2. The L. muta Venom-Induced Clotting
ETL (250 μg/mL) fully prevented L-muta-induced clotting and ETS delayed clotting so that it took around eight times longer, when compared to control value (L. muta incubated with DMSO or saline) that clotted plasma in around 60 seconds (Figure 2). When venom was incubated with EAS or EAL, plasma clotted around 300 and 150 seconds, respectively (Figure 2). On the other hand, HES or HEL did not inhibit clotting induced by venom. DMSO (0.5% v/v, final concentration) did not interfere on clotting time induced by L. muta venom (Figure 2).
3.3. The L. muta Venom-Induced Hemolysis
The extracts ETL or EAS (176 μg/mL) inhibited 100% hemolysis induced by L. muta venom, while ETS or HES inhibited circa of 95% and HEL and ETL inhibited 75% and 60% hemolysis, respectively (Figure 3).
3.4. The L. muta Venom-Induced Hemorrhage
L. muta venom (1.56 μg/g) injected into mice induced a hemorrhage halo of 20 mm that represents two MHD. But, in mice injected with venom mixed with ETL, ETS, EAS, or EAL (15.6 μg/g), the mice were fully protected from hemorrhage induced by the venom (Figure 4). HEL inhibited the hemorrhage halo by 46% such activity and HES did not protect mice from L. muta-induced hemorrhage (Figure 4). However, when L. muta venom was injected into mice 15 minutes prior to or after ETS or ETL, protection was not observed anymore (results not shown).
3.5. The L. muta Venom-Induced Edema
ETL (7.3 μg/g) fully inhibited the formation of edema induced by L. muta venom (0.73 μg/g), and ETS inhibited around 70% (Figure 5). HES and EAS inhibited edema below 5% and for EAS or EAL, 40 and 60% inhibition was observed. DMSO (1% v/v) neither interfered on hemorrhagic or edema of venom nor induced hemorrhage.
Snakebites represent an important public health problem, mainly in rural and poor areas of developing countries, and because of that, they are considered neglected diseases according to World Health Organization. L. muta snakebites cause pain, edema, necrosis, hemorrhage, vascular disturbances, and death. Since the antiserum treatment is not so effective against local effects, it is necessary to search for alternative or complementary methods in order to efficiently neutralize such effects. Native people have used plants and their metabolites to treat several diseases, including snake bite , and the literature has proven their efficacy as well as their metabolites against some harmful activities of snake venoms .
Thus, in this work, we tested the ability of ethanolic crude extracts from stem and leaves of M. subsericea and also their soluble fractions (hexane-soluble and ethyl acetate-soluble) to inhibit some toxic and harmful activities induced by L. muta venom. Overall, extracts of the stem and leaves of M. subsericea as well as its fractions inhibited such activities. Their inhibition occurred around 90% the proteolytic activity of L. muta venom that has been associated with some symptoms that follow snakebites, as hemorrhage and/or clotting. As seen, extracts of stem or leaves inhibited clotting and hemorrhage induced by L. muta venom and thus would prevent bleeding or vascular disturbances caused by L. muta bites. ETL inhibited clotting more efficiently than ETS, but EAS was the most powerful to prevent clotting. In addition, ETS, ETL, EAS, and EAL inhibited 100% hemorrhage induced by L. muta. Hemorrhage induced by snake venoms may occur through activating blood clotting and/or degrading specific proteins (as fibrinogen) of the blood cascade system. Metalloproteases and serine proteases are responsible for such harmful effects. Data from the literature state that plants or their products, mainly those enriched in phenolic compounds , inhibit hemorrhage by chelating metal ions that are essential for the action of metalloproteases and serine proteases [9, 30, 31]. Other plants constituents, as flavonoids, xanthenes, and terpenoids, may also bind to the catalytic site of enzymes and, in turn, inhibit their enzymatic activity [32, 33]. Previous reports have identified components isolated from the root of Hemidesmus indicus  or from Vitex negundo and Emblica officinalis  able to neutralize lethal, hemorrhagic, clotting, and inflammatory activities of Viper venom, probably through an antioxidant action . Phospholipases A2 promote several harmful activities, including hemolysis, platelet aggregation, edema, and myotoxicity [25, 37, 38], and as seen, M. subsericea interfered on some of these effects. ETS, ETL, HES, and HEL of M. subsericea inhibited 100% hemolysis, but only ETL fully protected mice from edema. ETS or EAL inhibited edema above 60% and EAS inhibited it by 40%. Polar and nonpolar secondary metabolites have been described as responsible for the inhibition of PLA2 in snake venom . Besides plants, other natural products are inhibitors of PLA2 enzymes, such as diterpenes from the marine brown algae Spatoglossum schröederi  or Canistrocarpus cervicornis . In addition, these algae also inhibited clotting and hemorrhagic activities induced by L. muta venom [31, 40]. Proteolysis, edema, and hemorrhage contribute to and/or are responsible for the local effects observed in victims after snakebite, which lead to amputation or morbidity in victims. Previous reports have indicated the presence of beta- and alpha-amyrin esters, such as their acetates, caprylates, and caproates in the hexanic extracts of leaves and stems [13, 22] that had antivenom properties. Moreover, spectroscopic analysis indicates the presence of some flavonoids, as quercetin, myricetin, and kaempferol-like in the ethyl acetate-soluble fraction of stems or leaves of M. subsericea (unpublished data). It should be mentioned that these substances displayed antivenom activity  and may be partially responsible for the inhibitory properties observed at the present study.
Since M. subsericea extracts inhibited in vivo (hemorrhagic and edematogenic) and in vitro (hemolytic, proteolytic, and clotting) harmful activities induced by L. muta venom, they may have a potential to the development of an alternative or complementary treatment for snakebites caused by L. muta.
Conflict of Interests
The authors declares that there is no conflict of interests regarding the publication of this paper.
The authors are grateful to Dra. Olga Maria Diniz Pereira for providing the blood bags and to Brazilian funding agencies (FAPERJ and CNPq) and UFF/PROPPi. Authors also want to thank Dr. Norman Ratcliffe, from Swansea University, United Kingdom for kindly revising the paper.
- J. M. Gutiérrez, H. W. Fan, C. L. M. Silvera, and Y. Angulo, “Stability, distribution and use of antivenoms for snakebite envenomation in Latin America: report of a workshop,” Toxicon, vol. 53, no. 6, pp. 625–630, 2009.
- J. M. Gutiérrez, G. León, and T. Burnouf, “Antivenoms for the treatment of snakebite envenomings: the road ahead,” Biologicals, vol. 39, no. 3, pp. 129–142, 2011.
- J. J. Calvete, L. Sanz, Y. Ângulo, B. Lomonte, and J. M. Gutiérrez, “Venoms, venomics, antivenomics,” FEBS Letters, vol. 583, no. 5, pp. 1736–1743, 2009.
- K. J. Clemetson, “Snaclecs (snake C-type lectins) that inhibit or activate platelets by binding to receptors,” Toxicon, vol. 56, no. 7, pp. 1236–1246, 2010.
- J. A. Campbell and W. W. Lamar, The Venomous Reptiles of Latin America, Cornell University Press, Ithaca, NY, USA, 1989.
- J. M. Gutiérrez, “Comprendiendo los venenos de serpientes: 50 años de investigaciones en América Latina,” Revista de Biologia Tropical, vol. 50, no. 2, pp. 377–394, 2002.
- A. M. Soares, M. R. M. Fontes, and J. R. Giglio, “Phospholipase A2 myotoxins from Bothrops snake venoms: structure-function relationship,” Current Organic Chemistry, vol. 8, no. 17, pp. 1677–1690, 2004.
- World Health Organization, Guidelines for the Production Control and Regulation of Snake Antivenom Immunoglobulins, WHO, Geneva, Switzerland, 2010.
- W. B. Mors, M. C. do Nascimento, B. M. R. Pereira, and N. A. Pereira, “Plant natural products active against snake bite—the molecular approach,” Phytochemistry, vol. 55, no. 6, pp. 627–642, 2000.
- M. S. Santhosh, M. Hemshekhar, K. Sunitha et al., “Snake venom induced local toxicities: plant secondary metabolites as an auxiliary therapy,” Mini-Reviews in Medicinal Chemistry, vol. 13, no. 1, pp. 106–123, 2013.
- J. Vásquez, S. L. Jiménez, I. C. Gómez et al., “Snakebites and ethnobotany in the Eastern region of Antioquia, Colombia-the traditional use of plants,” Journal of Ethnopharmacology, vol. 146, no. 2, pp. 449–455, 2013.
- R. Gomes, M. C. B. Pinheiro, H. A. de Lima, and L. D. R. Santiago-Fernandes, “Biologia floral de Manilkara subsericea e de Sideroxylon obtusifolium (Sapotaceae) em restinga,” Revista Brasileira de Botânica, vol. 33, no. 2, pp. 271–283, 2010.
- C. P. Fernandes, A. L. Corrêa, J. F. R. Lobo et al., “Triterpene esters and biological activities from edible fruits of Manilkara subsericea (Mart.) Dubard, Sapotaceae,” BioMed Research International, vol. 2013, Article ID 280810, 7 pages, 2013.
- G. Misra and C. R. Mitra, “Mimusops manilkara, constituents of fruit and seed,” Phytochemistry, vol. 8, no. 1, pp. 249–252, 1969.
- C. Lavaud, G. Massiot, M. Becchi, G. Misra, and S. K. Nigam, “Saponins from three species of Mimusops,” Phytochemistry, vol. 41, no. 3, pp. 887–893, 1996.
- J. Ma, X.-D. Luo, P. Protiva et al., “Bioactive novel polyphenols from the fruit of Manilkara zapota (Sapodilla),” Journal of Natural Products, vol. 66, no. 7, pp. 983–986, 2003.
- A. Cáceres, H. Menéndez, E. Méndez et al., “Antigonorrhoeal activity of plants used in Guatemala for the treatment of sexually transmitted diseases,” Journal of Ethnopharmacology, vol. 48, no. 2, pp. 85–88, 1995.
- R. Nair and S. Chanda, “Antimicrobial activity of Terminalia catappa, Manilkara zapota and Piper betel leaf extract,” Indian Journal of Pharmaceutical Sciences, vol. 70, no. 3, pp. 390–393, 2008.
- S. Muelas-Serrano, J. J. Nogal, R. A. Martínez-Díaz, J. A. Escario, A. R. Martínez-Fernández, and A. Gómez-Barrio, “In vitro screening of American plant extracts on Trypanosoma cruzi and Trichomonas vaginalis,” Journal of Ethnopharmacology, vol. 71, no. 1-2, pp. 101–107, 2000.
- J. Desrivot, J. Waikedre, P. Cabalion et al., “Antiparasitic activity of some New Caledonian medicinal plants,” Journal of Ethnopharmacology, vol. 112, no. 1, pp. 7–12, 2007.
- C. P. Fernandes, A. L. Corrêa, R. A. S. Cruz et al., “Anticholinesterasic activity of Manilkara subsericea (Mart.) Dubard triterpenes,” Latin American Journal of Pharmacy, vol. 30, no. 8, pp. 1631–1634, 2011.
- C. P. Fernandes, A. Xavier, J. P. Pacheco et al., “Laboratory evaluation of the effects of Manilkara subsericea (Mart.) Dubard extracts and triterpenes on the development of Dysdercus peruvianus and Oncopeltus fasciatus,” Pest Management Science, vol. 69, no. 2, pp. 292–301, 2013.
- G. M. Cragg, D. J. Newman, and S. S. Yang, “‘Natural product extracts of plant and marine origin having antileukemia potential’ the NCI experience,” Journal of Natural Products, vol. 69, no. 3, pp. 488–498, 2006.
- E. S. Garcia, J. A. Guimarães, and J. L. Prado, “Purification and characterization of a sulfhydryl-dependent protease from Rhodnius prolixus midgut,” Archives of Biochemistry and Biophysics, vol. 188, no. 2, pp. 315–322, 1978.
- A. L. Fuly, O. L. Machado, E. W. Alves, and C. C. Carlini, “Mechanism of inhibitory action on platelet activation of a phospholipase A2 isolated from Lachesis muta (Bushmaster) snake venom,” Thrombosis and Haemostasis, vol. 78, no. 5, pp. 1372–1380, 1997.
- H. Kondo, S. Kondo, H. Ikegawa, and R. Murata, “Studies on the quantitative method for determination of hemorrhagic activity of habu snake venom,” Japanese Journal of Medical Science and Biology, vol. 13, no. 1-2, pp. 43–52, 1960.
- M. Yamakawa, M. Nozani, and Z. Hokama, “Fractionation of sakishima-habu (Trimeresurus elegans) venom and lethal hemorrhagic, and edema forming activities of the fractions,” in Toxins: Animal, Plant and Microbial, A. Ohsaka, K. Hayashi, and Y. Sawai, Eds., pp. 97–120, Plenum Press, New York, NY, USA, 1976.
- R. C. de Paula, E. F. Sanchez, T. R. Costa et al., “Antiophidian properties of plant extracts against Lachesis muta venom,” Journal of Venomous Animals and Toxins Including Tropical Diseases, vol. 16, no. 2, pp. 311–323, 2010.
- J. Leanpolchareanchai, P. Pithayanukul, and R. Bavovada, “Anti-necrosis potential of polyphenols against snake venoms,” Immunopharmacology and Immunotoxicology, vol. 31, no. 4, pp. 556–562, 2009.
- B. O. Owuor and D. P. Kisangau, “Kenyan medicinal plants used as antivenin: a comparison of plant usage,” Journal of Ethnobiology and Ethnomedicine, vol. 2, article 7, pp. 1–8, 2006.
- T. F. S. Domingos, F. A. Ortiz-Ramirez, R. C. Villaça et al., “Inhibitory effect of a Brazilian marine brown alga Spatoglossum schröederi upon biological activities of Lachesis muta snake venom,” Brazilian Journal of Pharmacognosy, vol. 22, no. 4, pp. 741–747, 2012.
- B. Havsteen, “Flavonoids, a class of natural products of high pharmacological potency,” Biochemical Pharmacology, vol. 32, no. 23, pp. 1141–1148, 1983.
- Z. E. Selvanayagam, S. G. Gnanavendhan, K. Balakrishna et al., “Ehretian one, a novel quinonoid xanthene from Ehretia buxifolia with antisnake venom activity,” Journal of Natural Products, vol. 59, no. 7, pp. 664–667, 1996.
- M. I. Alam, B. Auddy, and A. Gomes, “Isolation, purification and partial characterization of viper venom inhibiting factor from the root extract of the Indian medicinal plant sarsaparilla (Hemidesmus indicus R.br.),” Toxicon, vol. 32, no. 12, pp. 1551–1557, 1994.
- M. I. Alam and A. Gomes, “Snake venom neutralization by Indian medicinal plants (Vitex negundo and Emblica officinalis) root extracts,” Journal of Ethnopharmacology, vol. 86, no. 1, pp. 75–80, 2003.
- A. Bhattacharya, A. Chatterjee, S. Ghosal, and S. K. Bhattacharya, “Antioxidant activity of active tannoid principles of Emblica officinalis (amla),” Indian Journal of Experimental Biology, vol. 37, no. 7, pp. 676–680, 1999.
- J. M. Gutiérrez and B. Lomonte, “Phospholipases A2: unveiling the secrets of a functionally versatile group of snake venom toxins,” Toxicon, vol. 62, no. 5, pp. 27–39, 2013.
- V. C. Carregari, R. S. Floriano, L. Rodrigues-Simioni et al., “Biochemical, pharmacological, and structural characterization of new basic PLA2 Bbil-TX from Bothriopsis bilineata snake venom,” BioMed Research International, vol. 2013, Article ID 61264, 12 pages, 2013.
- R. P. Samy, P. Gopalakrishnakone, and V. T. K. Chow, “Therapeutic application of natural inhibitors against snake venom phospholipase A2,” Bioinformation, vol. 8, pp. 48–57, 2012.
- L. A. Moura, E. F. Sanchez, E. M. Bianco, R. C. Pereira, V. L. Teixeira, and A. L. Fuly, “Antiophidian properties of a dolastane diterpene isolated from the marine brown alga Canistrocarpus cervicornis,” Biomedicine & Preventive Nutrition, vol. 1, no. 1, pp. 61–66, 2011.